MX2019012505A - Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso. - Google Patents

Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.

Info

Publication number
MX2019012505A
MX2019012505A MX2019012505A MX2019012505A MX2019012505A MX 2019012505 A MX2019012505 A MX 2019012505A MX 2019012505 A MX2019012505 A MX 2019012505A MX 2019012505 A MX2019012505 A MX 2019012505A MX 2019012505 A MX2019012505 A MX 2019012505A
Authority
MX
Mexico
Prior art keywords
dimethoxyquinolin
cyclopropane
oxy
phenyl
salts
Prior art date
Application number
MX2019012505A
Other languages
English (en)
Spanish (es)
Inventor
M Blazey Charles
Shah Khalid
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62683441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019012505(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2019012505A publication Critical patent/MX2019012505A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
MX2019012505A 2017-05-26 2018-05-26 Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso. MX2019012505A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511714P 2017-05-26 2017-05-26
PCT/US2018/034784 WO2018218233A1 (en) 2017-05-26 2018-05-26 Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Publications (1)

Publication Number Publication Date
MX2019012505A true MX2019012505A (es) 2019-12-19

Family

ID=62683441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012505A MX2019012505A (es) 2017-05-26 2018-05-26 Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.

Country Status (20)

Country Link
US (3) US11279675B2 (https=)
EP (1) EP3630726B1 (https=)
JP (3) JP7166292B2 (https=)
KR (1) KR102611445B1 (https=)
CN (1) CN110621662B (https=)
AU (1) AU2018272088C1 (https=)
CA (1) CA3060370A1 (https=)
DK (1) DK3630726T3 (https=)
EA (1) EA039654B1 (https=)
ES (1) ES2909390T3 (https=)
HU (1) HUE058196T2 (https=)
IL (1) IL270780B2 (https=)
MA (1) MA48776A (https=)
MX (1) MX2019012505A (https=)
PL (1) PL3630726T3 (https=)
PT (1) PT3630726T (https=)
SG (1) SG11201909161PA (https=)
UA (1) UA127760C2 (https=)
WO (1) WO2018218233A1 (https=)
ZA (1) ZA201906127B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016018450A2 (pt) * 2014-02-14 2018-09-18 Exelixis Inc formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
MA48776A (fr) * 2017-05-26 2020-04-08 Exelixis Inc Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation
CN117402114A (zh) 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
TWI831259B (zh) 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 包含達沙替尼十二烷基硫酸鹽組合物的膠囊
KR102828472B1 (ko) 2018-12-13 2025-07-03 엑셀리시스, 인코포레이티드 키나아제 억제제의 결정질 형태 및 염 형태
MX2021014773A (es) * 2019-06-03 2022-01-18 Exelixis Inc Formas de sales cristalinas de un inhibidor de cinasas.
EP4486725A1 (en) 2022-03-01 2025-01-08 Synthon B.V. Cabozantinib salt with l-(+)-tartaric acid and solid forms thereof
WO2024163400A1 (en) 2023-01-31 2024-08-08 Handa Oncology, Llc Improved cabozantinib compositions and methods of use
US11814356B1 (en) 2023-03-29 2023-11-14 Apotex Inc. Salt of cabozantinib

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
NZ779754A (en) * 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
EA030435B1 (ru) 2010-07-16 2018-08-31 Экселиксис, Инк. ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ
US20140057908A1 (en) 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
MX352926B (es) 2010-09-27 2017-12-14 Exelixis Inc Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
BR112013020362A2 (pt) 2011-02-10 2018-05-29 Exelixis Inc processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
MX2013012695A (es) 2011-05-02 2014-03-27 Exelixis Inc Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
EP2758057B1 (en) 2011-09-22 2017-05-31 Exelixis, Inc. Method for treating osteoporosis
US9535315B2 (en) 2011-10-31 2017-01-03 Applied Materials, Inc. Method of fabricating a color filter array using a multilevel structure
IN2014CN04067A (https=) 2011-11-08 2015-10-23 Exelixis Inc
TW201323864A (zh) 2011-11-08 2013-06-16 Exelixis Inc 定量癌症治療之方法
CN104649969B (zh) 2013-11-22 2019-02-12 广东东阳光药业有限公司 一种替尼类药物的盐及其制备方法
BR112016018450A2 (pt) * 2014-02-14 2018-09-18 Exelixis Inc formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
WO2015177758A1 (en) * 2014-05-23 2015-11-26 Mylan Laboratories Ltd Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base
CN104961680B (zh) 2014-11-07 2017-09-12 苏州晶云药物科技有限公司 N‑(4‑{[6,7‑双(甲基氧基)喹啉‑4‑基]氧基}苯基)‑n’‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺的盐酸盐及其多晶型
CN104961681B (zh) 2014-11-13 2017-06-13 苏州晶云药物科技有限公司 卡博替尼的粘酸盐及其晶型
EP3274333B1 (en) * 2015-03-25 2019-04-24 Sandoz AG Cabozantinib salts and their use as anti-cancer agents
EP3274332B1 (en) 2015-03-25 2018-12-19 Sandoz AG Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride
US10980792B2 (en) * 2016-09-12 2021-04-20 Zhuhai Beihai Biotech Co., Ltd. Formulations of Cabozantinib
WO2018104954A1 (en) * 2016-12-07 2018-06-14 Msn Laboratories Private Limited, R&D Center Process for the preparation of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2s)-hydroxybutanedioate and its polymorphs thereof
MA48776A (fr) * 2017-05-26 2020-04-08 Exelixis Inc Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation

Also Published As

Publication number Publication date
JP2024036690A (ja) 2024-03-15
US20210261509A1 (en) 2021-08-26
PL3630726T3 (pl) 2022-05-09
PT3630726T (pt) 2022-03-02
US11279675B2 (en) 2022-03-22
CN110621662B (zh) 2023-06-23
WO2018218233A1 (en) 2018-11-29
JP2020521732A (ja) 2020-07-27
AU2018272088A8 (en) 2019-10-24
AU2018272088B2 (en) 2022-06-16
JP2022145852A (ja) 2022-10-04
US20240010621A1 (en) 2024-01-11
EP3630726A1 (en) 2020-04-08
JP7166292B2 (ja) 2022-11-07
UA127760C2 (uk) 2023-12-27
JP7659097B2 (ja) 2025-04-08
NZ757564A (en) 2025-05-02
US11731941B2 (en) 2023-08-22
KR20200010205A (ko) 2020-01-30
EA201992803A1 (ru) 2020-04-16
US12227481B2 (en) 2025-02-18
AU2018272088A1 (en) 2019-10-17
IL270780B2 (en) 2025-04-01
ZA201906127B (en) 2022-11-30
SG11201909161PA (en) 2019-10-30
CN110621662A (zh) 2019-12-27
DK3630726T3 (da) 2022-03-07
HUE058196T2 (hu) 2022-07-28
KR102611445B1 (ko) 2023-12-06
EA039654B1 (ru) 2022-02-22
IL270780B1 (en) 2024-12-01
JP7437460B2 (ja) 2024-02-22
ES2909390T3 (es) 2022-05-06
IL270780A (en) 2020-01-30
EP3630726B1 (en) 2021-12-22
MA48776A (fr) 2020-04-08
US20220162166A1 (en) 2022-05-26
CA3060370A1 (en) 2018-11-29
AU2018272088C1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
MX2019012505A (es) Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
MX2016010266A (es) Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
MX372716B (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen.
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
CL2018001908A1 (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen.
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
EA201892450A1 (ru) Ароматические сульфонамидные производные
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
MX381707B (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
EA201691302A1 (ru) Новые гетероциклические соединения
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
MX372962B (es) Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
CU20170026A7 (es) Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
CL2017002354A1 (es) Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.
EA201891586A1 (ru) Антипролиферативные соединения и их фармацевтические композиции и применения
CL2021003568A1 (es) Compuestos heteroaromáticos como inhibidores de vanina (divisional de solicitud n° 202101198)
MY192425A (en) Polymorphs
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции
DOP2021000021A (es) Compuestos heteroaromáticos como inhibidores de vanina